BioMarin creates new-look R&D and deal teams with Roche’s Sabry, Amgen’s Friberg

BioMarin Pharmaceutical is shaking up its leadership team, raiding Amgen for an R&D chief to replace a departing company veteran and pulling off the coup of signing a high-profile former Roche dealmaker.